377 studies found for:    b49
Show Display Options
Rank Status Study
1 Active, not recruiting Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Paclitaxel
2 Completed
Has Results
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age
Condition: Healthy or Stable Underlying Chronic Medical Condition
Interventions: Biological: Q/LAIV-BFS (MEDI8662);   Biological: FluMist/B/Yamagata;   Biological: FluMist/B/Victoria
3 Completed
Has Results
Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old
Condition: Influenza
Interventions: Biological: Lot A of Influenza virus vaccine;   Biological: Lot B of Influenza virus vaccine;   Biological: Lot C of Influenza virus vaccine;   Biological: Comparator influenza virus vaccine;   Biological: All 3 consecutive lots of influenza virus vaccine pooled
4 Completed
Has Results
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age
Condition: Healthy or Stable Underlying Chronic Medical Condition
Interventions: Biological: Q/LAIV (MEDI3250);   Biological: FluMist/B/Yamagata;   Biological: FluMist/B/Victoria
5 Recruiting Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HIP2B;   Drug: Placebo
6 Completed Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
Condition: Influenza
Intervention: Biological: VAX161 [STF2.HA5 H5N1]
7 Terminated ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
Conditions: Multiple Myeloma;   Hematological Neoplasms
Intervention: Drug: Bortezomib
8 Completed Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults
Condition: Influenza
Intervention: Biological: Influenza Vaccine, recombinant Hemagglutinin
9 Active, not recruiting Cognitive Changes Associated With Breast Cancer Treatment
Conditions: Breast Cancer;   Cognitive Side Effects of Cancer Treatments;   Stage I, II and III A Breast Cancer
Intervention: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
10 Terminated B-19 Parvovirus Vaccine Study
Condition: Parvovirus B19 Infection
Interventions: Biological: VAI-VP705 (parvovirus B-19 vaccine);   Drug: Placebo;   Biological: MF-59
11 Completed
Has Results
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
Condition: Diabetes Melliuts, Type 2
Interventions: Other: Placebo;   Drug: 25 mg PF-05231023;   Drug: 50 mg PF-05231023;   Drug: 100 mg PF-05231023;   Drug: 150 mg PF-05231023
12 Completed Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)
Condition: Dermatitis
Interventions: Other: KLH 0.1 mg;   Other: KLH 5 mg;   Other: PBS (0.1 mL);   Other: Tuberculin PPD
13 Recruiting Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
Conditions: Vitamin B12 Deficiency;   Autoantibodies
14 Unknown  Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
Conditions: Colorectal Cancer;   Liver Metastases;   Irradiation Damage;   Radiation Induced Liver Disease
Interventions: Drug: Pentoxifylline;   Drug: Ursodeoxycholic Acid;   Drug: Enoxaparin
15 Unknown  A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma
Intervention: Radiation: 3DCRT or IMRT
16 Completed Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults
Condition: Influenza
Interventions: Biological: VAX128;   Biological: Placebo
17 Unknown  Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)
Condition: Chronic Hepatitis B
Intervention: Drug: Pegalyted interferon, Entecavir
18 Recruiting Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Drug: edoxaban;   Drug: Enoxaparin;   Drug: Warfarin
19 Recruiting Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Condition: HIV Infection
Intervention: Drug: Pegylated Interferon Alpha 2b (PEGINTRON)
20 Active, not recruiting Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Hematopoietic/Lymphoid Cancer;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin;   Drug: cyclophosphamide;   Biological: ofatumumab;   Procedure: laboratory biomarker analysis;   Other: flow cytometry;   Genetic: protein expression analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years